Literature DB >> 28755095

Neurological Adverse Effects Attributable to β-Lactam Antibiotics: A Literature Review.

Samuel Deshayes1,2, Antoine Coquerel3,4, Renaud Verdon5,6.   

Abstract

β-lactam antibiotics are commonly prescribed antibiotic drugs. To describe the clinical characteristics, risk markers and outcomes of β-lactam antibiotic-induced neurological adverse effects, we performed a general literature review to provide updated clinical data about the most used β-lactam antibiotics. For selected drugs in each class available in France (ticarcillin, piperacillin, temocillin, ceftazidime, cefepime, cefpirome, ceftaroline, ceftobiprole, ceftolozane, ertapenem and aztreonam), a systematic literature review was performed up to April 2016 via an electronic search on PubMed. Articles that reported original data, written in French, Spanish, Portuguese or English, with available individual data for patients with neurological symptoms (such as seizure, disturbed vigilance, confusional state, myoclonia, localising signs, and/or hallucinations) after the introduction of a β-lactam antibiotic were included. The neurological adverse effects of piperacillin and ertapenem are often described as seizures and hallucinations (>50 and 25% of cases, respectively). Antibiotic treatment is often adapted to renal function (>70%), and underlying brain abnormalities are seen in one in four to one in three cases. By contrast, the neurological adverse drug reactions of ceftazidime and cefepime often include abnormal movements but few hallucinations and seizures. These reactions are associated with renal insufficiency (>80%) and doses are rarely adapted to renal function. Otherwise, it appears that monobactams do not have serious neurological adverse drug reactions and that valproic acid and carbapenem combinations should be avoided. The onset of disturbed vigilance, myoclonus, and/or seizure in a patient taking β-lactam antibiotics, especially if associated with renal insufficiency or underlying brain abnormalities, should lead physicians to suspect adverse drug reactions and to consider changes in antibacterial therapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28755095     DOI: 10.1007/s40264-017-0578-2

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  16 in total

Review 1.  Intrathecal Antibacterial and Antifungal Therapies.

Authors:  Roland Nau; Claudia Blei; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

2.  Cost Impact Model of a Novel Multi-mRNA Host Response Assay for Diagnosis and Risk Assessment of Acute Respiratory Tract Infections and Sepsis in the Emergency Department.

Authors:  John E Schneider; Jonathan Romanowsky; Philipp Schuetz; Ivana Stojanovic; Henry K Cheng; Oliver Liesenfeld; Ljubomir Buturovic; Timothy E Sweeney
Journal:  J Health Econ Outcomes Res       Date:  2020-04-29

3.  Ceftaroline-associated Encephalopathy in Patients With Severe Renal Impairment.

Authors:  Thomas C S Martin; Sean Chow; Scott T Johns; Sanjay R Mehta
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079

Review 4.  Safety and tolerability of ceftobiprole.

Authors:  S Grau
Journal:  Rev Esp Quimioter       Date:  2019-09       Impact factor: 1.553

5.  Ceftaroline-Associated Encephalopathy: A Rare Adverse Effect.

Authors:  Aswin Srinivasan; Blake Bennie; Krina Viroliya; Ramesh Kesavan; Siva T Sarva
Journal:  Cureus       Date:  2021-05-01

Review 6.  Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?

Authors:  Erin F Barreto; Andrew J Webb; Gwendolyn M Pais; Andrew D Rule; Paul J Jannetto; Marc H Scheetz
Journal:  Crit Care Explor       Date:  2021-06-11

7.  Pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose intravenous ceftobiprole in healthy Chinese participants.

Authors:  Wan-Zhen Li; Hai-Lan Wu; Yuan-Cheng Chen; Bei-Ning Guo; Xiao-Fen Liu; Yu Wang; Ju-Fang Wu; Jing Zhang
Journal:  Ann Transl Med       Date:  2021-06

8.  Ertapenem-induced encephalopathy.

Authors:  Rebecca Adams; Priya Chopra; Richard Miranda; Aaron Calderon
Journal:  BMJ Case Rep       Date:  2020-06-01

9.  Successful Use of Ertapenem for the Treatment of Enterobacter cloacae Complex Infection of the Central Nervous System (CNS).

Authors:  Sunish Shah; Dayna McManus; Jeffrey E Topal
Journal:  Case Rep Infect Dis       Date:  2019-11-05

Review 10.  [Three keys to the appropriate choice of oral antibiotic treatment in the respiratory tract infections].

Authors:  R Menéndez; R Cantón; A García-Caballero; J Barberán
Journal:  Rev Esp Quimioter       Date:  2019-12-04       Impact factor: 1.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.